PKM2‐TMEM33 axis regulates lipid homeostasis in cancer cells by controlling SCAP stability

The pyruvate kinase M2 isoform (PKM2) is preferentially expressed in cancer cells to regulate anabolic metabolism. Although PKM2 was recently reported to regulate lipid homeostasis, the molecular mechanism remains unclear. Herein, we discovered an ER transmembrane protein 33 (TMEM33) as a downstream...

Full description

Saved in:
Bibliographic Details
Published inThe EMBO journal Vol. 40; no. 22; pp. e108065 - n/a
Main Authors Liu, Fabao, Ma, Min, Gao, Ang, Ma, Fengfei, Ma, Gui, Liu, Peng, Jia, Chenxi, Wang, Yidan, Donahue, Kristine, Zhang, Shengjie, Ong, Irene M, Keles, Sunduz, Li, Lingjun, Xu, Wei
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 15.11.2021
Springer Nature B.V
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The pyruvate kinase M2 isoform (PKM2) is preferentially expressed in cancer cells to regulate anabolic metabolism. Although PKM2 was recently reported to regulate lipid homeostasis, the molecular mechanism remains unclear. Herein, we discovered an ER transmembrane protein 33 (TMEM33) as a downstream effector of PKM2 that regulates activation of SREBPs and lipid metabolism. Loss of PKM2 leads to up‐regulation of TMEM33, which recruits RNF5, an E3 ligase, to promote SREBP‐cleavage activating protein (SCAP) degradation. TMEM33 is transcriptionally regulated by nuclear factor erythroid 2‐like 1 (NRF1), whose cleavage and activation are controlled by PKM2 levels. Total plasma cholesterol levels are elevated by either treatment with PKM2 tetramer‐promoting agent TEPP‐46 or by global PKM2 knockout in mice, highlighting the essential function of PKM2 in lipid metabolism. Although depletion of PKM2 decreases cancer cell growth, global PKM2 knockout accelerates allografted tumor growth. Together, our findings reveal the cell‐autonomous and systemic effects of PKM2 in lipid homeostasis and carcinogenesis, as well as TMEM33 as a bona fide regulator of lipid metabolism. SYNOPSIS This study identifies the endoplasmic reticulum (ER) transmembrane protein TMEM33 as a new mechanistic target of pyruvate kinase M2 (PKM2) and bona fide regulator of lipid metabolism. These findings have implications for cancer caused by elevated plasma cholesterol levels and underscore systemic functions of PKM2, opening up new avenues for therapeutic interventions. PKM2 down‐regulates TMEM33 expression in MEFs and breast cancer cells, derepressing the lipogenic transcription factor SREBP. TMEM33 is transcriptionally regulated by NRF1, whose activation depends on the PKM2/VCP axis. PKM2 loss induces TMEM33, leading it to recruit E3 ligase RNF5 for ubiquitination and degradation of SREBP‐cleavage factor SCAP. Depletion of PKM2 in mice elevates global cholesterol levels and promotes allografted growth of hepatocellular cancer. Graphical Abstract Transmembrane protein TMEM33 is a novel target of ER‐localised PKM2 and regulator of cholesterol metabolism.
Bibliography:See also
A Khateb & ZA Ronai
November 2021
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
See also: A Khateb & ZA Ronai (November 2021)
ISSN:0261-4189
1460-2075
1460-2075
DOI:10.15252/embj.2021108065